The Kell blood group system: Kell and XK membrane proteins.

Abstract:

:Two membrane proteins express the antigens that comprise the Kell blood group system. A single antigen, Kx, is carried on XK, a 440-amino acid protein that spans the membrane 10 times, and more than 20 antigens reside on Kell, a 93-kd, type II glycoprotein. XK and Kell are linked, close to the membrane surface, by a single disulfide bond between Kell cysteine 72 and XK cysteine 347. Although primarily expressed in erythroid tissues, Kell and XK are also present in many other tissues. The polymorphic forms of Kell are due to single base mutations that encode different amino acids. Some Kell antigens are highly immunogenic and may cause strong reactions if mismatched blood is transfused and severe fetal anemia in sensitized mothers. Antibodies to KEL1 may suppress erythropoiesis at the progenitor level, leading to fetal anemia. The cellular functions of Kell/XK are complex. Absence of XK, the McLeod phenotype, is associated with acanthocytic red blood cells (RBCs), and with late-onset forms of muscular dystrophy and nerve abnormalities. Kell, by homology, is a member of the neprilysin (M13) family of membrane zinc endopeptidases and it preferentially activates endothelin-3 by specific cleavage of the Trp21-Ile22 bond of big endothelin-3.

journal_name

Semin Hematol

journal_title

Seminars in hematology

authors

Lee S,Russo D,Redman CM

doi

10.1016/s0037-1963(00)90036-2

subject

Has Abstract

pub_date

2000-04-01 00:00:00

pages

113-21

issue

2

eissn

0037-1963

issn

1532-8686

pii

S0037-1963(00)90036-2

journal_volume

37

pub_type

杂志文章,评审
  • Recombinant factor VIIa (Novoseven) as a hemostatic agent.

    abstract::Recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Denmark) induces hemostasis in life- and limb-threatening bleeds and in major surgery of hemophilia A and B patients, regardless of inhibitor titer. A total of more than 6,500 patients have been treated, and NovoSeven has been administered in more than...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90147-7

    authors: Hedner U

    更新日期:2001-10-01 00:00:00

  • Novel agents in development for peripheral T-cell lymphoma.

    abstract::Though peripheral T-cell lymphoma (PTCL) is an area of significant unmet therapeutic need, a number of new treatment options are available for patients, especially those with relapsed or refractory disease. A plethora of drugs are now in development for PTCL, but drugs that truly target novel disease biology are notic...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2010.01.014

    authors: O'Connor OA

    更新日期:2010-04-01 00:00:00

  • Monoclonal antibodies in lymphoma: the first decade.

    abstract::The past decade has seen improvements in overall survival (OS) for patients with the two most common lymphoma histologies: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In FL, at least four independent datasets have confirmed these survival improvements. The monoclonal antibody rituximab has sign...

    journal_title:Seminars in hematology

    pub_type:

    doi:10.1053/j.seminhematol.2008.02.005

    authors: Link BK,Friedberg JW

    更新日期:2008-04-01 00:00:00

  • Myelodysplastic syndromes.

    abstract::These two issues of the Seminars in Hematology will provide the physician the necessary knowledge to help make sense of this somewhat confusing array of diseases. The subdivisions of MDS reflect the precision of our techniques of dissection, with morphological and histochemical analyses forming the foundation to ident...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Koeffler HP

    更新日期:1996-04-01 00:00:00

  • Survival signals in leukemic large granular lymphocytes.

    abstract::The central hypothesis of our laboratory research program in large granular lymphocyte (LGL) leukemia is that leukemic LGL represent antigen-driven cytotoxic T lymphocytes (CTL) with characteristics of dysregulated apoptosis. The clinical features of LGL leukemia highlight the association of autoimmune diseases such a...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(03)00135-5

    authors: Epling-Burnette PK,Loughran TP Jr

    更新日期:2003-07-01 00:00:00

  • Non-Diamond Blackfan anemia disorders of ribosome function: Shwachman Diamond syndrome and 5q- syndrome.

    abstract::A number of human disorders, dubbed ribosomopathies, are linked to impaired ribosome biogenesis or function. These include but are not limited to Diamond Blackfan anemia (DBA), Shwachman Diamond syndrome (SDS), and the 5q- myelodysplastic syndrome (MDS). This review focuses on the latter two non-DBA disorders of ribos...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2011.01.002

    authors: Burwick N,Shimamura A,Liu JM

    更新日期:2011-04-01 00:00:00

  • Transplant outcomes in bone marrow failure syndromes and hemoglobinopathies.

    abstract::Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potential cure for most bone marrow (BM) failure syndromes and hemoglobinopathies. Over the past decade, umbilical cord blood (UCB) has been used more frequently as a stem cell source in patients who lack a suitable BM donor. Although graft failure ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2009.10.004

    authors: MacMillan ML,Walters MC,Gluckman E

    更新日期:2010-01-01 00:00:00

  • Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes.

    abstract::High-dose chemoradiotherapy with allogeneic bone marrow or peripheral blood stem cell transplantation (SCT) is a potentially curative treatment for advanced or poor-prognosis hematological malignancies. This procedure was initially considered as a means to deliver supralethal doses of chemotherapy and radiation for th...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.30909

    authors: Giralt S,Anagnostopoulos A,Shahjahan M,Champlin R

    更新日期:2002-01-01 00:00:00

  • The new direct oral anticoagulants in special indications: rationale and preliminary data in cancer, mechanical heart valves, anti-phospholipid syndrome, and heparin-induced thrombocytopenia and beyond.

    abstract::The present review will briefly summarize the interplay between coagulation and inflammation, highlighting possible effects of direct inhibition of factor Xa and thrombin beyond anticoagulation. Additionally, the rationale for the use of the new direct oral anticoagulants (DOACs) for indications such as cancer-associa...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2014.03.002

    authors: Alberio L

    更新日期:2014-04-01 00:00:00

  • Treatment strategies for Hodgkin's disease.

    abstract::Over the past 2 decades, treatment of Hodgkin's disease has evolved considerably through innovations in the management of various stages. The impact of various treatments on the 5-, 10-, and 15-year results is being balanced against delayed morbidity, such as organ damage and second malignancies, produced by the inten...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Bonadonna G,Santoro A,Viviani S,Valagussa P

    更新日期:1988-04-01 00:00:00

  • Improving the safety profile of warfarin.

    abstract::Since warfarin remains the predominate drug administered for long-term anticoagulation, optimizing therapy for maximum antithrombotic effect with minimal bleeding risk continues to challenge clinicians. Genetic differences exist that affect an individual's response to warfarin. The clinician can use genetic informatio...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.34089

    authors: Chai SJ,Macik BG

    更新日期:2002-07-01 00:00:00

  • Neonatal thrombocytopenia and megakaryocytopoiesis.

    abstract::Thrombocytopenia is common among sick neonates, affecting 20% to 35% of all patients admitted to the neonatal intensive care unit (NICU). While most cases of neonatal thrombocytopenia are mild or moderate and resolve within 7 to 14 days with appropriate therapy, 2.5% to 5% of NICU patients develop severe thrombocytope...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2010.04.002

    authors: Ferrer-Marin F,Liu ZJ,Gutti R,Sola-Visner M

    更新日期:2010-07-01 00:00:00

  • Risks and benefits of erythropoiesis-stimulating agents in cancer management.

    abstract::Anemia is frequently diagnosed in patients with cancer and its treatment is an important clinical problem. The deficiency in red blood cells (RBCs) can be a debilitating problem, and anemia correlates with poor performance status, deteriorates quality of life, and may negatively influence the prognosis of cancer patie...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2007.04.004

    authors: Beutel G,Ganser A

    更新日期:2007-07-01 00:00:00

  • Familial thrombophilia: a complex genetic disorder.

    abstract::Familial thrombosis has long been considered as an autosomal dominant trait, caused by a dominant gene defect with a reduced penetrance for the disease. Recently, this view has changed and today familial thrombophilia is considered as a complex genetic disorder caused by the segregation of two or more gene defects (kn...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Koeleman BP,Reitsma PH,Bertina RM

    更新日期:1997-07-01 00:00:00

  • Development of early treatment strategies for high-risk myeloma precursor disease in the future.

    abstract::Smoldering myeloma (SMM) is a precursor state of multiple myeloma. It is defined by an M-protein concentration ≥3 g/dL and/or ≥10% clonal bone marrow plasma cells, in the absence of end-organ damage. Based on clinical observations, the natural history of SMM varies greatly, from stable, monoclonal gammopathy of undete...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2010.11.009

    authors: Landgren O,Rajkumar SV

    更新日期:2011-01-01 00:00:00

  • Antibody-targeted therapy for myeloid leukemia.

    abstract::The availability of antibodies reactive with antigens expressed only by hematopoietic cells has provided clinical investigators with new tools for use in developing therapies for acute myeloid leukemia (AML). Studies performed to date have investigated the use of such antibodies in an unmodified state, combined with p...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Appelbaum FR

    更新日期:1999-10-01 00:00:00

  • A rational approach to the diagnosis and management of thrombocytopenia in the hospitalized patient.

    abstract::Thrombocytopenia is one of the most common reasons for inpatient hematology consultations. The main challenges in the management of hospitalized patients with thrombocytopenia are to identify the underlying cause and to recognize when urgent interventions are required. Examination of the blood film is essential in the...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2011.08.002

    authors: Arnold DM,Lim W

    更新日期:2011-10-01 00:00:00

  • Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease.

    abstract::Because optimal management of iron chelation therapy in patients with sickle cell disease and transfusional iron overload requires accurate determination of the magnitude of iron excess, a variety of techniques for evaluating iron overload are under development, including measurement of serum ferritin iron levels, x-r...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90059-9

    authors: Brittenham GM,Sheth S,Allen CJ,Farrell DE

    更新日期:2001-01-01 00:00:00

  • Mismatched unrelated donor transplantation.

    abstract::There are now more than 25 million volunteer donors registered worldwide for patients in need of a life-saving hematopoietic cell transplant to cure blood disorders. Although a human leukocyte antigen (HLA)-matched donor remains the preferred stem cell source for transplantation, the use of a donor with limited HLA mi...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2016.07.003

    authors: Petersdorf EW

    更新日期:2016-10-01 00:00:00

  • Platelets in thrombotic disorders: quantitative and qualitative platelet disorders predisposing to arterial thrombosis.

    abstract::Endogenous thrombopoietin (TPO) stimulates platelet production in nonhuman primates by inducing dose-dependent megakaryocyte development from early marrow hematopoietic progenitors and subsequent proliferation and endoreduplication. In nonhuman primates, recombinant human TPO, nonpegylated or pegylated rHu megakaryocy...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Harker LA

    更新日期:1998-07-01 00:00:00

  • New therapeutic strategies in acute lymphoblastic leukemia.

    abstract::While cure rates of over 80% are achieved in contemporary pediatric acute lymphoblastic leukemia (ALL) protocols, most adults with ALL succumb to their disease, and little progress has been made in the treatment of refractory and relapsed ALL. Moreover, the burden of therapy is high in a significant number of newly di...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2008.09.009

    authors: Jeha S

    更新日期:2009-01-01 00:00:00

  • The use of topoisomerase I inhibitors in multiple myeloma.

    abstract::The standard treatment of multiple myeloma is systemic chemotherapy. Despite 30 years of drug development in myeloma, there are no new drug regimens significantly superior to melphalan and prednisone. In addition, phase II studies of new drugs in myeloma have been disappointing, with low response rates and no prolonga...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Kraut EH,Ju R,Muller M

    更新日期:1998-07-01 00:00:00

  • Prognostic relevance of clinical risk factors in mantle cell lymphoma.

    abstract::Mantle cell lymphoma (MCL) has only recently been recognized as a separate biologically defined lymphoma entity. Due to its low incidence, many reports on clinical prognostic factors are limited by small patient numbers. The MCL International Prognostic Index (MIPI) was developed using data of more than 400 patients t...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2011.06.001

    authors: Hoster E

    更新日期:2011-07-01 00:00:00

  • A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.

    abstract::This phase I trial of idarubicin (IDA) was conducted in 32 patients with acute leukemia and chronic myelogenous leukemia (CML) in blastic crisis (CML/BC) who either had failed to achieve a complete remission (CR) after initial induction therapy or had relapsed after CR. IDA was administered at dosages ranging from an ...

    journal_title:Seminars in hematology

    pub_type: 临床试验,杂志文章,评审

    doi:

    authors: Tamura K

    更新日期:1996-10-01 00:00:00

  • Leukocyte-endothelial cell interactions.

    abstract::Mechanisms that support migration of leukocytes have been studied extensively in vitro. The adhesion of neutrophils under conditions of flow at venous shear rates primarily involves members of the selectin family. E-selectin is upregulated by cytokine stimulation of endothelial cells (ECs); P-selectin is upregulated b...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Smith CW

    更新日期:1993-10-01 00:00:00

  • Future strategies toward the cure of indolent B-cell malignancies. Immune recognition and antiself.

    abstract::Tumor cells from patients with B-cell malignancies exhibit a number of immunophenotypic characteristics that may be responsible for their survival. It has been shown, for example, that down-modulation of CD154 (CD40 ligand), which allows B cells to respond to T cells, may account for some of the immune defects of thes...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Nadler LM

    更新日期:1999-10-01 00:00:00

  • Control of late neutrophil-specific gene expression: insights into regulation of myeloid differentiation.

    abstract::During myeloid differentiation, the pluripotent hematopoietic stem cell passes through several well-defined morphologic stages within the bone marrow. These changes include progressive nuclear segmentation and the acquisition of stage-specific granules. Primary granules appear at the myeloblast stage, and are found in...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Sigurdsson F,Khanna-Gupta A,Lawson N,Berliner N

    更新日期:1997-10-01 00:00:00

  • Apoptosis and cancer: strategies for integrating programmed cell death.

    abstract::Virtually all human cells are endowed with the capacity to commit suicide using an evolutionarily conserved mechanism that involves activation of caspase-family cell death proteases. Caspase activation culminates in a cell death process known as "apoptosis." The activation of these intracellular proteases is carefully...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90055-6

    authors: Reed CJ

    更新日期:2000-10-01 00:00:00

  • Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.

    abstract::This report suggests modest changes in the criteria used for the diagnosis of ET and allows tentative recommendations concerning therapy. As outlined in Table I, we believe that absent stainable marrow iron does not necessarily indicate iron deficiency in these patients and that the serum ferritin and RBC mean corpusc...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Murphy S,Peterson P,Iland H,Laszlo J

    更新日期:1997-01-01 00:00:00

  • The manufacturing process for recombinant factor IX.

    abstract::Advances in recombinant DNA manufacturing technology have now made possible the production of a highly purified and active recombinant factor IX (rFIX) product. Recombinant factor IX was developed by (1) stable insertion of the genes for both factor IX and PACE-SOL (a truncated, soluble serine protease needed to enhan...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Harrison S,Adamson S,Bonam D,Brodeur S,Charlebois T,Clancy B,Costigan R,Drapeau D,Hamilton M,Hanley K,Kelley B,Knight A,Leonard M,McCarthy M,Oakes P,Sterl K,Switzer M,Walsh R,Foster W

    更新日期:1998-04-01 00:00:00